Core Insights - Progyny reported Q3 CY2025 results that exceeded market revenue expectations, with a year-on-year sales increase of 9.3% to $313.3 million [1][4] - The company raised its full-year Adjusted EPS guidance to $1.81, reflecting a 3.7% increase [6] Financial Performance - Revenue for Q3 CY2025 was $313.3 million, surpassing analyst estimates of $299.3 million, representing a 9.3% year-on-year growth and a 4.7% beat [6] - Adjusted EPS was $0.45, exceeding analyst expectations of $0.39 by 15.4% [6] - Adjusted EBITDA reached $54.97 million, beating analyst estimates of $47.11 million, with a margin of 17.5% [6] - Operating margin improved to 6.9%, up from 4.3% in the same quarter last year [6] - Sales volumes increased by 7.2% year on year [6] Guidance and Future Outlook - Q4 CY2025 revenue guidance is set at $300.2 million, slightly below analyst estimates of $302.2 million [6] - EBITDA guidance for Q4 CY2025 is $47.3 million, above analyst estimates of $46.78 million [6] - Management anticipates ongoing demand for family building and women's health services, supported by new product offerings targeting small and midsized businesses [5] - The company is well-positioned for continued growth, with a focus on disciplined investment in platform expansion and acquisitions [5][4]